Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2230808 | 0.80 | USP2 (0.35) | USP2 | |
| SCHEMBL9801010 | 0.76 | — | — | |
| SCHEMBL21028208 | 0.75 | PIK3CD (0.31) | — | |
| SCHEMBL23555211 | 0.73 | TP53 (0.32) | — | |
| SCHEMBL15531853 | 0.71 | MEN1 (0.40) | — | |
| SCHEMBL9801300 | 0.69 | GRM5 (0.30) | — | |
| SCHEMBL2744441 | 0.68 | KDM4E (0.41) | — | |
| SCHEMBL3176003 | 0.68 | KEAP1 (0.36) | — | |
| SCHEMBL25098955 | 0.68 | PKM (0.32) | — | |
| SCHEMBL25098677 | 0.68 | PKM (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318120-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210251968-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC. (US) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251968-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | USP2 3954/4885 |
| US-11318120-B2 | Nuclear transport modulators and uses thereof | XPO1, XPO5, XPOT | USP2 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.